SeaStar Medical Q3 EPS Estimate Reduced by Zacks Research

SeaStar Medical Holding Corporation (NASDAQ:ICU) – Analysts at Zacks Research reduced their Q3 2026 earnings per share (EPS) estimates for shares of SeaStar Medical in a report released on Monday, August 17th. Zacks Research analyst D. Bautz now anticipates that the company will post earnings per share of ($0.95) for the quarter, down from their previous forecast of ($0.89). The consensus estimate for SeaStar Medical’s current full-year earnings is ($3.58) per share. Zacks Research also issued estimates for SeaStar Medical’s FY2026 earnings at ($3.66) EPS.

ICU has been the topic of a number of other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a report on Friday, July 17th. Maxim Group set a $8.00 price objective on SeaStar Medical and gave the stock a “buy” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen upgraded shares of SeaStar Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.00.

SeaStar Medical Stock Performance

NASDAQ ICU opened at $3.27 on Thursday. The company has a fifty day moving average of $3.69 and a 200-day moving average of $3.43. SeaStar Medical has a 52-week low of $2.07 and a 52-week high of $12.50. The company has a market capitalization of $14.42 million, a P/E ratio of -0.84 and a beta of -1.05.

SeaStar Medical (NASDAQ:ICU) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.06. SeaStar Medical had a negative return on equity of 162.75% and a negative net margin of 795.51%.The firm had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.49 million.

Institutional Trading of SeaStar Medical

A number of institutional investors have recently made changes to their positions in ICU. XTX Topco Ltd grew its position in SeaStar Medical by 395.4% in the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock worth $26,000 after purchasing an additional 48,674 shares during the period. Millennium Management LLC bought a new stake in shares of SeaStar Medical during the 3rd quarter valued at $102,000. Finally, Jane Street Group LLC purchased a new position in shares of SeaStar Medical in the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 1.69% of the company’s stock.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.